APPROVED FOR THE TREATMENT OF IPF AND SSc-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline (Infographics)
Document ID: PC-CRP-103653
25/04/2023
Author: Boehringer Ingelheim
RELATED CONTENT
PC-CRP-103653
Production Date: April 2023
Production Date: April 2023
